Secondary analysis of RENOVATE (1,766 adults with acute respiratory failure; high-flow nasal oxygen vs non-invasive ventilation) using sequential likelihood ratios: HFNO benefit in cardiogenic pulmonary oedema (−11.0%), possible harm in COVID-19 (+4.3%), masked when pooled.
Secondary analysisn = 1,766
Zampieri et al. Sequential likelihood ratios and e-processes in the analysis of the RENOVATE trial